Opportunities to enhance protections for individualized interventions involving gene-editing
Open Access
- 12 September 2026
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (4)
Abstract
No abstract availableFunding Information
- Greenwall Foundation
This publication has 14 references indexed in Scilit:
- A fatal reactionScience, 2026
- Progress in the Development of N-of-1 TherapyNew England Journal of Medicine, 2025
- Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic DiseaseNew England Journal of Medicine, 2025
- A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseasesNature Communications, 2024
- Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy ResponsesNucleic Acid Therapeutics, 2022
- Individualized therapy trials: navigating patient care, research goals and ethicsNature Medicine, 2021
- A Professional Standard for Informed Consent for Stem Cell TherapiesJAMA, 2019
- Patient-Funded Trials: Opportunity or Liability?Cell Stem Cell, 2015
- Questions Concerning the Clinical Translation of Cell-Based Interventions under an Innovation PathwayJournal of Law, Medicine & Ethics, 2012
- Genetic Research as Therapy: Implications of “Gene Therapy” for Informed ConsentJournal of Law, Medicine & Ethics, 1998